Tanner Pharma Group has announced the signing of a distribution agreement with Partner Therapeutics, (PTx), an integrated biopharmaceutical company. The agreement names Tanner Pharma Group as a distributor of Leukine (sargramostim) in areas outside of the United States and Canada where the product is not yet registered. Leukine (sargramostim) is used to help increase the number and function of white blood cells after bone marrow transplantation.
The ex-US-and-Canadian distribution will be managed by TannerGAP, a wholly owned subsidiary of Tanner Pharma Group.
“We have customized a program for Partner Therapeutics through which we can fulfill healthcare provider requests for Leukine (sargramostim) in countries outside the US and Canadian markets,” Banks Bourne, Chairman and Founder of Tanner Pharma Group, said. “TannerGAP is pleased to be working with Partner Therapeutics to expand the distribution of Leukine (sargramostim) to patients in need around the world.”